ANTLER Phase 1 trial of CB-010
94% overall response rate (ORR). 69% of patients achieved a complete response (CR) as best response following a single dose of CB-010 allogeneic CAR-T cell therapy. 44% of patients had a CR at ≥6 months post-CB-010 administration.
Format
PNG
Source
Caribou Biosciences, Inc.